Performance analysis of Sensei Biotherapeutics (SNSE)
Annual Return
Over the past 3 years, SNSE has had an average annual return of -17.06%, underperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, SNSE has had an average annual return of -42.04%, underperforming the benchmark SPY, which returned +14.05% annual.
Since Feb 4, 2021, SNSE has had an average annual return of -44.71%, underperforming the benchmark SPY, which returned +15.08% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| +51.06% | +8.88% | -29.23% | -53.55% | -74.32% | -69.31% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.99% | +221.51% | +3.35% | -15.59% | -20.60% | -23.79% | +51.06% | ||||||
| 2025 | -3.86% | -0.80% | -15.79% | +2.40% | -24.88% | +41.88% | -12.78% | +11.62% | +13.12% | -2.80% | -8.23% | +26.46% | +8.88% |
| 2024 | +18.58% | +3.69% | +23.56% | -2.88% | -27.59% | -16.11% | +6.40% | -8.02% | -1.56% | -20.57% | +13.94% | -9.44% | -29.23% |
| 2023 | -6.73% | +13.06% | -4.45% | -0.76% | -2.03% | -21.89% | +10.61% | -20.69% | -20.04% | -11.11% | +1.33% | -3.94% | -53.55% |
| 2022 | -16.91% | -25.10% | -36.02% | -32.90% | +22.56% | +19.50% | -15.82% | +0% | -18.89% | -6.46% | -2.09% | +4.93% | -74.32% |
| 2021 | -12.70% | -11.94% | -8.88% | -6.11% | -21.48% | -19.15% | +36.62% | -2.42% | -17.39% | -20.84% | -15.69% | -69.31% |
Drawdown analysis of Sensei Biotherapeutics (SNSE)
The maximum drawdown for the SNSE was -98.73%, occurring on Apr 4, 2025. This drawdown has not yet recovered.
The current SNSE drawdown is -96.46%.
Since Feb 4, 2021 SNSE has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.73% | Feb 8, 2021 | 1044 | Apr 4, 2025 | Ongoing | Ongoing | Ongoing |